Relationship Between High Density Lipoprotein Antioxidant Activity and Carotid Arterial Intima-Media Thickness in Patients with Essential Hypertension

REFERENCES

• von Eckardstein A, Nofer JR, Assmann G. Acceleration of reverse cholesterol transport. Current Opinion in Cardiology 2000;15:348–354.
   PubMed Web of Science ®Google Scholar
• Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, . Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751–2756.
   PubMed Web of Science ®Google Scholar
• Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: Beyond reverse cholesterol transport. Atherosclerosis 2002; 161:1–16.
   PubMed Web of Science ®Google Scholar
• Mancini GB, Dahlof B, Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 2004;109:IV22–30.
   PubMedGoogle Scholar
• de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, Kastelein JJ. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004;109:III33–38.
   PubMed Web of Science ®Google Scholar
• Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129–135.
   PubMed Web of Science ®Google Scholar
• Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidative capacity. Free Radical Research 2003; 37(1):77–83.
   PubMed Web of Science ®Google Scholar
• Yang YH, Xia Y, Yuan SH, He L. Relationship between activity of PON21 and coronary artery disease. Clinical Focus 2005;20:1–3.
   Google Scholar
• Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Castaldo M, Fontana L, . The paraoxonase promoter polymorphism (-107)T > C is not associated with carotid intima-media thickness in Sicilian hypercholesterolemic patients. Clinical Biochemistry 2004;37(5): 388–394.
   PubMed Web of Science ®Google Scholar
• Cao HB, Girard-Globa A, Serusclat A, Bernard S, Bondon P, Picard S, Lack of association between carotid intima-media thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus. Atherosclerosis 1998;138(2):361–366.
   PubMed Web of Science ®Google Scholar
• Harangi M, Seres I, Magyar MT, Csipo I, Sipka S, Valikovics A, . Association between human paraoxonase 1 activity and intima-media thickness in subjects under 55 years of age with carotid artery disease. Cerebrovasc Dis 2008;25:122–128.
   PubMed Web of Science ®Google Scholar
• Zhang LH, Liu BW. Separation of human serum lipoproteins by one-step density gradient ultracentrifugation. Acta Biochimica et Biophysica Sinica 1989;21:257–260.
   Google Scholar
• Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6:67–75.
   PubMed Web of Science ®Google Scholar
• Zago V, Sanguinetti S, Brites F, Berg G, Verona J, Basilio F, Wikinski R, . Impaired high density lipoprotein antioxidative activity in healthy postmenopausal women. Atherosclerosis 2004;177:203–210.
   PubMed Web of Science ®Google Scholar
• Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126–1138.
   PubMed Web of Science ®Google Scholar
• Kastelein JJP, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, . Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. New England Journal of Medicine 2007;356: 1620–1630.
   PubMed Web of Science ®Google Scholar
• Steven EN, Jean CT, Stephen JN, Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, . Effect of torcetrapib on the progression of coronary atherosclerosis. New England Journal of Medicine 2007;356:1304–1316.
   PubMed Web of Science ®Google Scholar
• Bots ML,Visseren FL, Evans GW, Riley WA, Shear CL, Duggan WT, . Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial. New England Journal of Medicine 2007;370:153–160.
   Google Scholar
• Jurek A, Turyna B, Kubit P, Klein A. LDL susceptibility to oxidation and HDL antioxidative capacity in patients with renal failure. Clin Biochem 2006;39:19–27.
   PubMed Web of Science ®Google Scholar
• Sanguinetti SM, Brites FD, Fasulo V, Verona J, Elbert A, Wikinski R L, . HDL oxidability and its protective effect against LDL oxidation in type 2 diabetic patients. Diabetes Nutr Metab 2001;14:27–36.
   PubMedGoogle Scholar
• Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004;15:399–404.
   PubMed Web of Science ®Google Scholar
• Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, . Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529–541.
   PubMed Web of Science ®Google Scholar